Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form

Thrombosis and Haemostasis

Volumn 79, Issue 1, 1998, Pages 169-176

  Refino, Canio J ^a   Modi, Nishit B ^a   Bullens, Sherron ^a   Pater, Cheryl ^a   Lipari, Michael T ^a   Robarge, Kirk ^a   Blackburn, Brent ^a   Beresini, Maureen ^a   Weller, Thomas ^b   Steiner, Beat ^b   Bunting, Stuart ^a  

^a GENENTECH INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; FIBRINOGEN RECEPTOR ANTAGONIST; PRODRUG; RO 443888; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; BLEEDING TIME; BLOOD PRESSURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHESUS MONKEY; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

EID: 0031974072     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614238     Document Type: Article

References (50)

1. Stein B, Fuster V, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk. Circulation 1989; 80: 1501-13.
2. Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol 1991; 17 (suppl B): 89B-95B.
3. Coller BS. Platelets and thrombolytic therapy. N Engl J Med 1990; 322: 33-42.
4. Davies MJ, Thomas AC. Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-73.
5. Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose JA. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326: 287-91.
6. Fuster V, Jang IK. Role of Platelet-inhibitor agents in coronary artery disease. In: Textbook of Interventional Cardiology. Topol EJ (ed). Philadelphia, PA: W.B. Saunders, 1994: 3-22.
7. Barnathan ES, Schwartz JS, Taylor L, Laskey WK, Kleaveland JP, Kussmaul WG, Hirshfeld JW Jr. Aspirin and Dipyridamole in the prevention of acute coronary thrombosis. Circulation 1987; 76: 125-34.
8. White HD, Charbonnier B, Van de Werf F, Erhardt L, David D, Hillis WS, von der Lippe G, Verbeugt FWA, Jennings G, Braun D, Fitzpatrick V, Sax FL. An aspirin controlled study of MK-852 in patients with unstable angina (abstr). Circulation 1993; 88: I-201.
9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction and stroke by prolonged antiplatet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
10. O'Brien J. Effects of salicylates on human platelets. Lancet 1968; 1: 779-83.
11. Saltiel E, Ward A. Ticlopidine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet dependent disease states. Drugs 1987; 87: 222.
12. Mills DCB, Puri R, Hu CJ, Minniti G, Grana G, Freedman MD, Colman RF, Colman RW. Clopidogrel inhibits the binding of ADP analoques to the receptor mediating inhibition of platelet adenylate cyclase. Arteriosclerosis Thromb 1992; 12: 430.
13. Grotemeyer K-H, Scharafinski H-W, Husstedt I-W. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot study including 180 post-stroke patients. Thromb Res 1993; 71: 397-403.
14. Turitto VT, Baumgartner HR. Platelet surface interactions. In: Hemostasis and thrombosis, basic principles and clinical practices. Colman RW, Hirsh J, Marder VJ, Salzmann EW, ed. Philadelphia, PA: J. B. Lippencott Company, 1982: 364-79.
15. Collar BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101-8.
16. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988; 71: 831-43.
17. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-84.
18. Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 1996; 17: 9-18.
19. Willerson JT. Inhibitors of platelet glycoprotein IIb/IIIa receptors: Will they be useful when given chronically? Circulation 1996; 94: 866-8.
20. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
21. Topol EJ, Califf RM, Wiesman HF, Ellis SG, Tscheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT, on behalf of the EPIC Investigators. Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994; 343: 881-6.
22. Blackburn BK, Gadek TR. Glycoprotein IIb/IIIa antagonists. Annu Rep Med Chem 1993; 28: 79-88.
23. Weller T, Alig L, Hurzeler Muller M, Kouns WC, Steiner B. Fibrinogen receptor antagonists - a novel class of promising antithrombotics. Drugs of the future 1994; 19: 461-76.
24. Ojima L, Chakravarty S, Dong Q. Antithrombotic agents: from RGD to peptide mimetics. Bioorg med chem 1995; 3: 337-60.
25. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, for the IMPACT Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation 1995; 91: 2151-7.
26. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton J, Weaver WD, McKee D, Fitzpatrick V, Sax FL. Randomized, double blind, placebo controlled dose ranging study of Tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996; 27: 536-42.
27. Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, fung AY, Boudreault JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ, on Behalf of the Investigators. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian Lamifiban Study. Circulation 1996; 94 (6): 899-905.
28. Alig L, Edenhofer A, Hadvary P, Hurzeler M, Knopp D, Muller M, Steiner B, Trzeciak A, Weller T. Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992; 35: 4393-407.
29. Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadvary P, Muller MH, Knopp D, Levet-Trafit B, Lipari MT, Modi NB, Muller M, Refino CJ, Schmitt M, Schönholzer P, Weiss S, Steiner B. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J Med Chem 1996; 39 (16): 3139-47.
30. Tanswell P, Koup J. Topfit: a PC-based pharmacokinetics/pharmacodynamics data analysis program. Int J Clin Pharmacol Toxicol 1993; 31: 514-20.
31. Beck WS. Hematology. (third ed.) Cambridge, Mass and London, England: MIT Press, 1983: 283.
32. Folts JD, Smith SO. Acute platelet thrombus formation in stenosed monkey carotid arteries: inhibited with aspirin, restored temporarily with epinephrine (abstr). J AM Coll Cardiol 1985; 5: 468.
33. Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang I-K, Holt R, Fallon JT, Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion, and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-22.
34. Simoons ML, deBoer MJ, van den Brand MJ, van Miltenburg AJ, Hoomtje JCA, Heyndrickx GR, and the European Cooperative Study Group. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994; 89: 596-603.
35. Schulman SP, Goldschmidt-Clermont PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AD, Ferguson JJ, Harington RA, Lincoff Am, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Angerson HV, Nygaard TW, Mason SJ, Effron MB, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G. The effects of Integrelin, a platelet glycoprotein IIb-IIIa receptor antagonist, in unstable angina: the importance of gender differences in the response to antiplatelet therapy. Circulation 1996; 94: 359-67.
36. Cannon CP, Novotny WF, McCabe CH, Tischler MD, Borzak S, Henry TD, Feldman R, Hamilton S, Rothman JM, Braunwald E, and the TIMI Investigators. Evaluation of the oral glycoprotein IIb/IIIa antagonist Ro 48-3657 in patients post Acute Coronary Syndromes: primary results of the TIMI 12 Trial (abstr). Circulation 1996; 94 (8): I-552.
37. Barrett JS, Murphy G, Peerlinck K, DeLepeleire I, Gould RJ, Panebianco D, Hand E, Deckmyn H, Vermylen J, Arnout J. Pharmacokinetics and pharmacodynamics of MK383, a selective non-peptide platelet glycoprotein IIb/IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994; 56: 377-88.
38. Duggan ME, Naylor-Olsen AM, Perkins JJ, Anderson PS, Chang C T-C, Cook JJ, Gould RJ, Ihle NC, Hartman GD, Lynch JJ, Lynch RJ, Manno PD, Schaffer LW, Smith RL. Non-peptide fibrinogen receptor antagonists. XX. Design and synthesis of the potent, orally active fibrinogen receptor antagonist L-734,217. J Med Chem 1995; 38: 3332-41.
39. Muller TH, Schurer H, Waldmann L, Bauer E, Himmelsbach F, Binder K. Oral activity of BIBU 104, a prodrug of the non-peptide fibrinogen receptor antagonist BIBU 52, in mice and monkeys (Abstr). Thromb Haemost 1993; 69: 675.
40. Nicholson NS, Panzer-Knodle SG, Salyers AK, Taite BB, Salzony JA, Haas MF, King LW, Zablocki JA, Keller BT, Broschat K. An orally active inhibitor of platelet aggregation. Circulation 1995; 91: 403-10.
41. Mousa SA, DeGrado WF, Mu D-X, Kapil RP, Lucchesi BR, Reilly TM. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist. Circulation 1996; 93: 537-43.
42. Funk C, Scheuermann G, Haas R, Viger-Chougnet A. Reduction of the aromatic amidoximes by subcellular fractions of rat liver. 2nd Annual Conference on Pharmacogenetics. Arlington, VA, 1996.
43. Mordenti J, Chappell W. The use of interspecies scaling in toxicokinetics. In: Yacobi A, Skelly J, Batra V, ed. Toxicokinetics and new drug development. New York: Pergamon Press, 1989: 42-96.
44. Coller BS, Scudder LE, Beer J, Gold HK, Folts JD, Cavagnaro J, Jordan R, Wagner C, Iuliucci J, Knight D, Ghrayeb J, Smith C, Weisman HF, Berger H. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann NY Acad Sci 1991; 614: 193-213.
45. Peerlink K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J. MK-383 (L-700, 462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist is active in man. Circulation 1993; 88: 1512-7.
46. Tschopp JF, Mazur C, Gould K, Connolly R, Pierschbacher MD. Inhibition of thrombosis by a selective fibrinogen receptor antagonist without effect on bleeding time. Thromb Haemost 1994; 72 (1): 119-24.
47. Hawiger J, Kloczewiak M, Bednarek MA, Timmons S. Platelet receptor recognition domains on the A chain of human fibrinogen: structure-function analysis. Biochemistry 1989; 28: 2909-14.
48. Dennis MS, Henzel WJ, Pitti RM, Lipari MT, Napier MA, Deisher TA, Bunting S, Lazarus RA. Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet aggregation inhibitors. Proc Natl Acad Sci USA 1989; 87: 2471-5.
49. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86: 651-9.
50. Frank JD, Gould RJ, Schaffer LW, Davidson JT, Gibson RE, Patrick DH, Vonderfecht SL, Cartwright ME. Immunocytochemical localization of platelets in baboon hepatic sinusoids using monoclonal mouse anti-human platelet glycoprotein IIIa following induction of thrombocytopenia. Histochem 1992; 97: 355-60.